NVO250110P92000
- 7.84
- 0.000.00%
Novo-Nordisk A/S Newsroom
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk Analyst Ratings
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
Novo Nordisk's CagriSema Selloff Is Overdone, UBS Says -- Market Talk
Novo-Nordisk A/S (NVO.US) expands its collaboration with Valo Health with a massive investment of 4.6 billion USD to co-develop new cardiac metabolism medications.
The Danish pharmaceutical giant Novo-Nordisk A/S announced on Wednesday an expansion of its collaboration with the AI biotechnology company Valo Health, aiming to accelerate the development of new therapies for cardiometabolic diseases.
Novo Nordisk Shares Are Trading Higher After the Company Entered Into an Expanded Agreement With Valo Health to Discover and Develop Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease.
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
Ozempic Maker Novo Nordisk, After Trial Disappointment, Expands AI Deal in Potential $4.6 Billion Pact
Facebook Moderation Move Is a Mistake. Why -2-
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk Target Cut to DKK750 From DKK1,100 by UBS
Novo Nordisk Raised to Buy From Neutral by UBS
Novo Nordisk Needs Answers to These 5 Key Questions
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
Danish Stocks Mixed as Trump Threatens Tariffs to Acquire Greenland
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Variant Bio Announces Multi-Year Research Partnership With Novo Nordisk to Discover Novel Targets for Metabolic Disease
Express News | Bernstein: Raised the Target Price for Novo-Nordisk A/S from 560 Danish kroner to 600 Danish kroner.